PharmaShots Weekly Snapshot (Dec 30, 2019-Jan 03, 2020)
1. RedHill Terminates its 2014 Deal with Salix Pharmaceuticals for RHB-106
Published: Jan 03, 2019 | Tags: 2014, Deal, RedHill, RHB-106, Salix Pharmaceuticals, Terminates
Published: Jan 03, 2019 | Tags: EMA, Hairy Cell Leukemia, Innate, Lumoxit, MAA, moxetumomab pasudotox-tdfk, Patients, Receives, Refractory, Relapsed, Treat
Published: Jan 02, 2019 | Tags: Acute, Graft-Versus-Host Disease, GRAVITAS-301, Incyte, Itacitinib, P-III study, Patients, Reports, Results, Treatment-Naïve
Published: Jan 02, 2019 | Tags: Agreement, Arena, Beacon Discovery, Develop, Immune, Inflammatory Diseases, Multi-Year, Signs, Therapies
5. Johnson & Johnson Signs a License Agreement with Pulmatrix to Develop Therapies for Lung Cancer
Published: Jan 02, 2019 | Tags: Agreement, Develop, Johnson & Johnson, License, Lung Cancer, Pulmatrix, Signs, Therapies
6. Amgen Signs an Agreement with BeiGene for the Expansion of its Oncology Footprints in China
Published: Jan 02, 2019 | Tags: Agreement, Amgen, BeiGene, China, Expansion, Footprints, Oncology, Signs
7. Sol-Gel Reports Results of Twyneo in Two P-III Trials for Acne Vulgaris
Published: Dec 30, 2019 | Tags: Acne Vulgaris, P-III, reports, results, Sol-Gel, Trials, Two, Twyneo
8. Roche Signs an AI-Based Research Agreement with Sensyne Health
Published: Dec 23, 2019 | Tags: Agreement, AI based, Research, Roche, Sensyne Health, Signs
9.MappBio Collaborates with Aridis Pharmaceuticals to Develop Therapies Utilizing APEX Technology
Published: Dec 30, 2019 | Tags: APEX Technology, Aridis Pharmaceuticals, Collaborates, Develop, MappBio, Therapies, Utilizing
Published: Dec 30, 2019 | Tags: AXS-07, Axsome Therapeutics, History, Inadequate Response, Migraine Trial, Momentum Phase 3, Patients, Reports, Results
11. MorphoSys Reports Submission of Tafasitamabs BLA to the US FDA to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
Published: Dec 31, 2019 | Tags: B-Cell Lymphoma, BLA, Diffuse, Large, MorphoSys, r/r DLBCL, Refractory, Relapsed, reports, Submission, Tafasitamab, Treat, Us FDA
12. Clover Reports First Patient Dosing in P-III Trial with SCB-808 (biosimilar, etanercept) in China
Published: Dec 30, 2019 | Tags: Biosimilar, Clover, Dosing, First, P-III, Patient, reports, SCB-808, Trial
13. GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology
Published: Dec 30, 2019 | Tags: Agreement, Develop, GenScript, Immuno- Oncology, Selecxine, Signs, Therapies
Published: Dec 30, 2019 | Tags: Acceleron, Agreement, Fulcrum, Identification, License, Pulmonary Diseases, Signs, Therapies, Treat
Published: Dec 27, 2019 | Tags: 2L, approval, BeiGene, cHL, Classical Hodgkin Lymphoma, NMPA, receives, Tislelizumab, Treatment
Published: Dec 30, 2019 | Tags: Clinical Trial, Eli Lilly, LIBRETTO-531, LOXO-292, MTC, Opens, P-III, patients, RET-Mutant Medullary Thyroid Cancer, Selpercatinib, Treat
Published: Dec 30, 2019 | Tags: 1L, approval, AstraZeneca, BRCA-Mutated, Germline, Lynparza, Maintenance, Merck & Co, Metastatic Pancreatic Cancer, Receive, the US FDA, Treatment
Published: Dec 27, 2019 | Tags: (niraparib), approval, China, Maintenance Therapy, NMPA, Ovarian Cancer, patients, receives, Recurrent, Zai Lab, Zejula
Published: Dec 30, 2019 | Tags: DAYVIGO, Disorder, Eisai, Insomnia, Lemborexant, P-III, Patients, Report, results, SUNRISE 1
20. Pharming to Reacquire Exclusive Commercialization Rights for its Ruconest from Sobi
Published: Dec 30, 2019 | Tags: Commercialization, Exclusive, Pharming, Reacquire, Right, Ruconest, Sobi
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com